Deal facts
- Buyer
- Ayrmid Ltd.
- Target
- Karyopharm Therapeutics Inc.
- Deal value
- Not disclosed
- Announced
- 2 November 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- United States
- Consideration
- shares, earn-out
Sources
Karyopharm Therapeutics Inc. and its subsidiary KPT Texas LLC filed voluntary Chapter 11 petitions on November 2, 2026 in the U.S. Bankruptcy Court for the Southern District of Texas, Houston Division. The same day they signed a Restructuring Support Agreement with lenders and noteholders holding 100% of the company's funded debt, certain revenue interest investors, certain holders of its convertible preferred stock, and Ayrmid Ltd. Under that agreement Ayrmid is the stalking horse bidder for a merger between Ayrmid and the reorganized company. Before filing, Centerview Partners contacted numerous strategic and financial counterparties, and the process produced five non-binding indications of interest.
Under the Ayrmid term sheet, holders of funded debt claims and the DIP lenders would receive 100% of the reorganized company's common stock on the plan's effective date. That stock would be exchanged for 55% of NewCo, with Ayrmid's existing stockholders receiving the other 45%, subject to certain adjustments. Funded debt holders would also receive contingent value rights tied to future net sales of XPOVIO (selinexor) for myelofibrosis. Existing common stock, convertible preferred stock and other equity interests would be cancelled with no distribution. NewCo would also enter a new senior secured term loan of up to $135 million, with proceeds used to repay up to $50 million of new money DIP loans. The filing does not state an aggregate purchase price for the Ayrmid transaction.
Ayrmid is majority-owned by funds managed by Highbridge Capital Management, LLC, and certain Highbridge funds also hold loans and notes under the company's funded debt. The filing says Highbridge recused itself from deliberations on the sale process and the evaluation of Ayrmid's proposal. Ayrmid's offer is the minimum bid and remains open to higher or better bids. Its bid protections are a break-up fee of 3% of the Bid Protection Base and expense reimbursement capped at 1% of that base. If another bid is chosen, Ayrmid has agreed to act as back-up bidder until the earlier of that transaction closing or 110 days after the petition date. Consenting stakeholders may support an alternative only if it pays at least $335.4 million at closing, and under the bidding procedures a successful bid needs a minimum closing payment of $363.6 million.
The filing describes a $110 million superpriority DIP facility, of which up to $55 million is new money and the rest is roll-up loans. Voting on the prepackaged plan closes November 30, 2026, and the debtors are seeking a confirmation hearing on or about January 11, 2027, subject to court availability. Completion requires a court order approving the transaction and any required regulatory approvals. The company expects the Ayrmid transaction to close in the first quarter of 2027.
The archive tags include an earn-out. Compare completion cash, deferred payments and earn-outs before treating a headline amount as proceeds. Check the underlying announcement for the actual conditions; tags are not a complete payment schedule.
Deal timeline
1 update- Firm intention
Ayrmid Ltd. M&A filing involving Karyopharm Therapeutics Inc.
Item 1.01. Entry into a Material Definitive Agreement. The information set forth below in Item 1.03 and Item 2.03 of this Current Report on Form 8-K is incorporated herein by reference. Item 1.03. Bankruptcy or Receivership. On November 2, 2026 (the “Petition Date”), Karyopharm Therapeutics Inc. (the “Company”) and its subsidiary, KPT Texas LLC (the “Subsidiary” and, together with the Company, the
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Drugs Made In America Acquisition II Corp. to acquire Alpha AI Biotech Group
Drugs Made in America Acquisition II Corp., a Cayman Islands special purpose acquisition company listed on Nasdaq, disclosed in a Form 8-K signed November 18, 2026 that…
- Buyer
- Drugs Made In America Acquisition II Corp.
- Target
- Alpha AI Biotech Group
- Deal value
- USD 600,000,000
- Deal type
- strategic acquisition
Aimei Health Technology Co., Ltd to acquire Hera Health Solutions Inc.
Aimei Health Technology Co., Ltd (Nasdaq: AFJK), a Cayman Islands blank check company, entered into a non-binding letter of intent on November 14, 2026 for a business co…
- Buyer
- Aimei Health Technology Co., Ltd
- Target
- Hera Health Solutions Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Wolfram Resources Plc to acquire Ellipses Pharma Limited
Wolfram Resources Plc (LSE: WFR), a Main Market listed special purpose acquisition company, confirmed on 16 November 2026 that it was in active discussions about a poten…
- Buyer
- Wolfram Resources Plc
- Target
- Ellipses Pharma Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
MaxCyte, Inc. to acquire Akron BioProducts LLC
MaxCyte, Inc., the Nasdaq-listed cell-engineering company, has agreed to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management. The Securities P…
- Buyer
- MaxCyte, Inc.
- Target
- Akron BioProducts LLC
- Deal value
- USD 151,800,000
- Deal type
- strategic acquisition
Buyer history
Ayrmid Ltd.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive